Soleno Therapeutics (SLNO) said the US Food and Drug Administration approved the company's VYKAT XR tablets to treat hyperphagia in adults and children with Prader-Willi Syndrome, a rare genetic disorder.
The approval was based on efficacy and safety data from a phase 3 trial, the company said Wednesday in a statement.
Soleno expects VYKAT XR to be available in the US in April.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.